ArticleOncotarget2015

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.

Matthew B Siegel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.